7 results on '"Dichgans, Martin"'
Search Results
2. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL
- Author
-
Dichgans, Martin, Markus, Hugh S, Salloway, Stephen, Verkkoniemi, Auli, Moline, Margaret, Wang, Qin, Posner, Holly, and Chabriat, Hugues S
- Subjects
- *
PARASYMPATHOMIMETIC agents , *CHOLINESTERASE inhibitors , *DEMENTIA , *ALZHEIMER'S disease , *MEDICAL sciences - Abstract
Summary: Background: Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer''s disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL''s early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL. Methods: 168 patients with CADASIL (mean age 54·8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n=82) by a computer-generated randomisation protocol. Inclusion criteria included a mini-mental state examination (MMSE) score of 10–27 or a trail making test (TMT) B time score at least 1·5 SD below the mean, after adjustment for age and education. The primary endpoint was change from baseline in the score on the vascular AD assessment scale cognitive subscale (V-ADAS-cog) at 18 weeks. Secondary endpoints included scores on the ADAS-cog, MMSE, TMT A time and B time, Stroop, executive interview-25 (EXIT25), CLOX, disability assessment for dementia, and sum of boxes of the clinical dementia rating scale. Analysis was done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00103948. Findings: 161 patients were analysed. There was no significant difference between donepezil (n=84) and placebo (n=77) in the primary endpoint. The least-squares mean change from baseline score was −0·81 (SE 0·59) in the placebo group and −0·85 (SE 0·57) in the donepezil group (p=0·956). There was a significant treatment effect favouring donepezil on the following secondary outcomes: TMT B time (p=0·023), TMT A time (p=0·015), and EXIT25 (p=0·022). Ten donepezil-treated patients discontinued treatment due to adverse events compared to seven placebo-treated patients. Interpretation: Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment. Improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear. Our findings may have implications for future trial design in subcortical vascular cognitive impairment. Funding: Eisai Medical Research (Ridgefield Park, NJ, USA). [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
3. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum
- Author
-
Dichgans, Martin
- Subjects
- *
CEREBROVASCULAR disease risk factors , *DEMENTIA - Abstract
Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) an inherited small vessel disease leading to subcortical strokes and dementia. Since the vascular pathology is clearly defined, CADASIL may provide important insights into the mechanisms underlying lacunar infarcts, ischemic white matter changes, and vascular dementia. Evidence from different sources suggests a central role for vascular smooth muscle cells (VSMC) in the pathophysiology of the disease. This article gives a brief overview on the phenotypic spectrum of the disease and discusses some of the relevant disease mechanisms that lead from Notch3 mutations to ischemic infarcts. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
4. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel.
- Author
-
Iadecola, Costantino, Duering, Marco, Hachinski, Vladimir, Joutel, Anne, Pendlebury, Sarah T., Schneider, Julie A., and Dichgans, Martin
- Subjects
- *
UNILATERAL neglect , *ALZHEIMER'S disease , *DEMENTIA , *DISABILITIES , *ETIOLOGY of diseases ,WESTERN countries - Abstract
Cognitive impairment associated with aging has emerged as one of the major public health challenges of our time. Although Alzheimer's disease is the leading cause of clinically diagnosed dementia in Western countries, cognitive impairment of vascular etiology is the second most common cause and may be the predominant one in East Asia. Furthermore, alterations of the large and small cerebral vasculature, including those affecting the microcirculation of the subcortical white matter, are key contributors to the clinical expression of cognitive dysfunction caused by other pathologies, including Alzheimer's disease. This scientific expert panel provides a critical appraisal of the epidemiology, pathobiology, neuropathology, and neuroimaging of vascular cognitive impairment and dementia, and of current diagnostic and therapeutic approaches. Unresolved issues are also examined to shed light on new basic and clinical research avenues that may lead to mitigating one of the most devastating human conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Hippocampal volume is an independent predictor of cognitive performance in CADASIL
- Author
-
O'Sullivan, Mike, Ngo, Elmar, Viswanathan, Anand, Jouvent, Eric, Gschwendtner, Andreas, Saemann, Philipp G., Duering, Marco, Pachai, Chahin, Bousser, Marie-Germaine, Chabriat, Hugues, and Dichgans, Martin
- Subjects
- *
HUNTINGTON disease , *DEMENTIA , *PSYCHOSES , *ISCHEMIA - Abstract
Abstract: Recent evidence suggests that hippocampal changes are present in vascular cognitive impairment but their importance and relationship with ischaemic mechanisms remain controversial. To investigate these issues we performed MRI and cognitive assessment in a large cohort (n =144) of patients with CADASIL, a hereditary small vessel disease and model of pure vascular cognitive impairment. Dementia status was ascribed according to DSM-IV and global cognitive function assessed with the Minimental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Hippocampal volume (HV) correlated with age (r =−0.33, p <0.001), brain volume (r =0.39, p <0.001) and lacunar lesion volume (r =−0.23, p =0.008), but not white matter lesions or microhaemorrhages. HV was reduced in dementia (2272±333mm3 versus 2642±349mm3, p <0.001) in the whole cohort and the subgroup progressing to dementia before age 60. HV correlated with MMSE (r =0.30, p <0.001), MDRS (r =0.40, p <0.001) and in a multivariate model predicted cognition independent of typical vascular lesions and whole brain atrophy. These findings strengthen the view that hippocampal atrophy is an important pathway of cognitive impairment in vascular as well as degenerative disease. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
6. Influence of SORL1 gene variants: Association with CSF amyloid-β products in probable Alzheimer's disease
- Author
-
Kölsch, Heike, Jessen, Frank, Wiltfang, Jens, Lewczuk, Piotr, Dichgans, Martin, Kornhuber, Johannes, Frölich, Lutz, Heuser, Isabella, Peters, Oliver, Schulz, Jörg B., Schwab, Sibylle G., and Maier, Wolfgang
- Subjects
- *
ALZHEIMER'S disease , *DEMENTIA , *PATHOLOGY , *DISEASES in older people - Abstract
Abstract: SORL1 gene variants were described as risk factors of Alzheimer''s disease (AD). We investigated the association of four SORL1 variants with CSF levels of Aβ42 and Aβ40 in 153 AD patients recruited from a multicenter study of the German Competence Net Dementias. Only one SORL1 SNP was associated with altered Aβ42 levels in the single marker analysis (SNP21: p =0.011), the other SNPs did not show an association with Aβ42 or Aβ40 CSF levels. Haplotype analysis identified a three marker SORL1 haplotype consisting of SNP19 T-allele, SNP21 G-allele and SNP23 A-allele (T/G/A) which was associated with reduced Aβ42 CSF levels in AD patients (p =0.003). Aβ40 levels were also lower in carriers of this haplotype; however, this did not reach statistical significance (p =0.15). We found a SORL1 haplotype which was associated with CSF levels of amyloid-β cleavage products, measured as altered levels of Aβ42. Thus our data suggest that SORL1 gene variants might influence AD pathology. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
7. Dementia after stroke due to intracerebral haemorrhage.
- Author
-
Salman, Rustam Al-Shahi, McGoohan, Katie, Rodrigues, Mark, Dichgans, Martin, and Al-Shahi Salman, Rustam
- Subjects
- *
TREATMENT of dementia , *CEREBRAL amyloid angiopathy , *NEURODEGENERATION , *CEREBRAL hemorrhage , *DISEASE complications , *FEMALES , *DISEASES , *DEMENTIA , *STROKE - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.